Viewing Study NCT00648050


Ignite Creation Date: 2025-12-24 @ 5:05 PM
Ignite Modification Date: 2026-02-09 @ 9:10 PM
Study NCT ID: NCT00648050
Status: COMPLETED
Last Update Posted: 2024-04-24
First Post: 2008-03-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to VerelanĀ® PM Extended-Release Capsules 300 mg
Sponsor: Mylan Pharmaceuticals Inc
Organization:

Organization Data

Organization:
Class: INDUSTRY
Study ID: VERA-0613
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type: None
Responsible Party Affiliation:
Old Name: Will Sullvan, Global Head of Product Risk and Safety Management
Old Organization: Mylan Inc.

Collaborators